What is Protectyn®?

Protectyn® is scientifically formulated to support healthy gut function and enhance gastrointestinal & liver health.

What is Protectyn®?

Protectyn® is an oral biopharmaceutical product that is scientifically formulated to contain high levels of active antibodies. These antibodies target pathogenic bacteria and harmful lipopolysaccharide (LPS) toxins they produce in the gut, reducing their ability to disrupt the healthy function of the gut, liver and immune system.

Protectyn® is not an antibiotic, and therefore does not promote antibiotic resistance.

Protectyn® helps to:

  • Enhance healthy digestive and gastrointestinal system health.
  • Promote good bacteria growth and restore friendly gut flora.
  • Maintain liver health and support healthy liver function.
  • Reduce mild gastrointestinal tract inflammation.
  • Maintain healthy gastrointestinal mucosal membrane health.
  • Aid and assist in the repair of the gut wall lining
  • Enhance immune defence and support healthy gastrointestinal immune function.
Liver Support Supplement

Protectyn® Ingredients

Active natural* ingredient
(main ingredient)
200 mg of highly immune bovine colostrum powder* formulates as a 700mg solid oral tablet.

The hyperimmune bovine colostrum contains over 80% proteins by weight, approximately 35% to 45% of which are immunoglobulins.

The very high levels of antibodies provide passive protection against a wide range of pathogens.

Other ingredients
(inactive ingredients)
Colloidal silicone dioxide, croscarmellose sodium, glucose, magnesium stearate and microcrystalline cellulose.
Potential allergensMilk proteins and lactose.

Do not take this medicine if you are allergic to any of these ingredients.

Lactose intolerance: The amount of lactose in Protectyn® has been reduced <10% which equates to <20mg/caplet which is considered well below the level any clinical symptoms are expected to be caused in lactose intolerant patients.


Protectyn® has been tested and shown to be gluten free.

Protectyn is a natural product derived from bovine colostrum enriched with anti-lipopolysaccharide (LPS) antibodies.

How to use Protectyn®

Protectyn® is a caplet which should be taken orally before every meal.

Directions for use: Take one or two caplets before every meal, three times per day or as directed by your healthcare practitioner.


Check with your health professional if you:

  • Have an allergy to milk or bovine proteins or a lactose intolerance. Symptoms may include digestive problems, such as bloating, constipation, diarrhoea or gas.
  • Are taking oral Tetracycline, as Protectyn® contains calcium.
  • Have diabetes as Protectyn® contains glucose.
  • Have a history of cancer.
  • Have liver or kidney disease or have been instructed to follow a low protein diet.
  • Suffer from an immune system disorder (eg, HIV/AIDS).

Pregnancy and breastfeeding
Check with your health professional if you are pregnant or intend to become pregnant, are breastfeeding or intend to breastfeed. Protectyn® is not on the TGA pregnancy database. However, Protectyn® has not been specifically tested on pregnant and nursing mothers.

For children under 6 years of age
Consult your health professional before using.

If symptoms persist, talk to your health professional.
Seek medical advice if diarrhoea persists for more than: 48 hours in adults and children over 6 years.

Protectyn® Technology

The active ingredient – Bovine Colostrum Powder (BCP) in Protectyn® is sourced from New Zealand and dairy cows that have been specifically “hyper-immunised” with patented Immuron vaccines by experienced and qualified veterinarians. These vaccines illicit a strong immune response which allows the cow to produce very high levels of specific antibodies, against pathogenic bacteria and harmful lipopolysaccharide (LPS) toxins. These anti-LPS antibodies bind to these bacteria and the toxins they produce, effectively neutralising and allowing them to be eliminated from the gastrointestinal tract before they can colonise, multiply and leak into the bloodstream, disrupting the digestive system.

Animal Health and Welfare Standards

Immuron has partnered with Synlait, an innovative and trusted dairy company based in New Zealand, for the supply of its bovine colostrum powder. Synlait specializes in the processing of infant formula and special milk powders and operates under an internationally accredited ISO/IEC 17065 dairy assurance system. Synlait only partners with certified dairy farmers which exceed New Zealand’s Animal Health and Welfare standards. In addition to this, Immuron’s commercial operations are managed by experienced and qualified veterinarians. A small portion of colostrum is harvested from selected dairy farms for processing, leaving plenty for the calves and standard dairy farm requirements.  The health and welfare of a herd impacts directly on milk quality. The best dairy farmers know this and work hard to ensure a happy, healthy herd. It’s the proactive steps they take today that help improve milk production tomorrow. Click here for more information on Synlait’s Lead with Pride programme.

Scientific studies

Clinical trials of IMM-124E (the active pharmaceutical ingredient used in Protectyn®)
Protectyn® underwent independent double-blinded placebo-controlled E.coli (ETEC) challenge trials in Europe and the USA. The trials showed protection of up to 90% against infection with E.coli (ETEC) and the development of diarrhoea. Participants who took dose regimens of 1 caplet (200 mg) and 2 caplets (400 mg) of Protectyn® three times a day had significantly less discomfort and diarrhoea compared to those who did not receive Protectyn®.

In vitro & pre-clinical studies of IMM-124E (the active pharmaceutical ingredient used in Protectyn®)
Pre-clinical studies were conducted to investigate the anti-inflammatory potential of Protectyn® in two mouse models of colitis. The results demonstrated that oral treatment with Protectyn® significantly reduces intestinal inflammation and confirmed that the administration of Protectyn® may represent a novel therapeutic strategy to induce or maintain remission in chronic colitis.

In another pre-clinical study stool samples were collected from mice treated with either Protectyn® or placebo for microbiome analysis. This mouse model demonstrated that Protectyn® increased the abundance of potential gut-beneficial bacteria, such as the genus Akkermansia, and reduced Clostridium (Clade III) without disrupting the underlying ecology of the gastrointestinal tract.

Various in vitro studies have shown that the antibodies in Protectyn ® can bind to a wide range of pathogenic gram-negative bacteria and the toxins they produce. The U.S. Department of Defense (DoD) conducted two studies using bacteria samples retrieved from infected personnel deployed in Southern Asia. The first study demonstrated that Protectyn® was able to bind and react to all 180 samples of pathogenic bacteria tested, including Campylobacter, ETEC (E.coli) and Shigella. The second study found that Protectyn® was also able to bind and react to all 71 samples of Vibrio cholera tested. Other studies conducted by Immuron’s Research partners have demonstrated that Protectyn® was also able to bind and react to pathogenic strains of Salmonella and Klebsiella.

Furthermore, in a pre-clinical study conducted by the US DoD, Protectyn® was shown to reduce the risk of infection with a pathogenic strain of Shigella in non-human primate challenge trials. All 100% (4 of 4) placebo treated animals displayed acute clinical signs of dysentery within 24 – 36 hours of a Shigella challenge. Only 2 of the 8 Protectyn® treated group displayed any signs of dysentery. The remaining 75% (6 of 8) of the Protectyn® treated group remained healthy and without signs of dysentery post challenge. Histopathological analysis, which provides a comprehensive view of the clinical disease and its effect on tissues of the gut, revealed that all animals in the placebo-treated group displayed severe inflammation in different parts of the gastrointestinal tract. Only 3 of the 8 Protectyn® treated animals had signs of inflammation in the gastrointestinal tract. All other animals in the Protectyn® treated group were clinically healthy and overall, the results suggest that Protectyn® is functionally cross-reactive and may have some prophylactic activity against Shigellosis.

Stay in touch